Trading Report: Today, Bank of Hawaii Raises its position in Becton Dickinson and Co. (BDX) as a favorable investment target.

Today, Bank of Hawaii Raises its position in Becton Dickinson and Co. (BDX) as a favorable investment target.

Bank of Hawaii boosted its stake in shares of Becton Dickinson and Co. (NYSE:BDX) by 0.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,215 shares of the company’s stock after buying an additional 27 shares during the period. Bank of Hawaii’s holdings in Becton Dickinson and were worth $578,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. RMB Capital Management LLC raised its stake in Becton Dickinson and by 19.2% in the third quarter. RMB Capital Management LLC now owns 87,477 shares of the company’s stock valued at $15,722,000 after buying an additional 14,089 shares during the period. Carderock Capital Management Inc. raised its stake in Becton Dickinson and by 72.7% in the third quarter. Carderock Capital Management Inc. now owns 13,702 shares of the company’s stock valued at $2,463,000 after buying an additional 5,766 shares during the period. Cardinal Capital Management raised its stake in Becton Dickinson and by 1.1% in the third quarter. Cardinal Capital Management now owns 29,029 shares of the company’s stock valued at $5,217,000 after buying an additional 328 shares during the period. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp raised its stake in Becton Dickinson and by 25.8% in the third quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 93,100 shares of the company’s stock valued at $16,733,000 after buying an additional 19,100 shares during the period. Finally, Advisor Partners LLC raised its stake in Becton Dickinson and by 1.7% in the third quarter. Advisor Partners LLC now owns 3,826 shares of the company’s stock valued at $688,000 after buying an additional 65 shares during the period. 82.68% of the stock is currently owned by institutional investors.

Becton Dickinson and Co. (NYSE:BDX) traded up 1.31% during trading on Friday, hitting $170.69. The stock had a trading volume of 489,615 shares. The firm has a market cap of $36.34 billion, a price-to-earnings ratio of 38.02 and a beta of 1.04. Becton Dickinson and Co. has a 1-year low of $129.50 and a 1-year high of $181.76. The firm’s 50 day moving average is $171.92 and its 200 day moving average is $172.32.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Thursday, November 3rd. The company reported $2.12 EPS for the quarter, topping the Zacks’ consensus estimate of $2.09 by $0.03. Becton Dickinson and had a return on equity of 24.44% and a net margin of 7.82%. The company had revenue of $3.23 billion for the quarter, compared to the consensus estimate of $3.22 billion. During the same quarter in the previous year, the business earned $1.94 EPS. The company’s quarterly revenue was up 5.6% compared to the same quarter last year. On average, analysts anticipate that Becton Dickinson and Co. will post $9.52 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 30th. Stockholders of record on Friday, December 9th will be paid a $0.73 dividend. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.71%. The ex-dividend date is Wednesday, December 7th. This is an increase from Becton Dickinson and’s previous quarterly dividend of $0.66. Becton Dickinson and’s payout ratio is currently 58.54%.

Several analysts have weighed in on the company. Zacks Investment Research raised Becton Dickinson and from a “hold” rating to a “buy” rating and set a $189.00 target price on the stock in a report on Friday. Leerink Swann reaffirmed a “market perform” rating and set a $185.00 price objective (up previously from $180.00) on shares of Becton Dickinson and in a research note on Monday. Deutsche Bank AG reaffirmed a “buy” rating and set a $189.00 price objective (down previously from $197.00) on shares of Becton Dickinson and in a research note on Friday, November 4th. Argus reaffirmed a “buy” rating and set a $185.00 price objective on shares of Becton Dickinson and in a research note on Friday, October 21st. Finally, Citigroup Inc. lowered Becton Dickinson and from a “neutral” rating to a “sell” rating and decreased their price objective for the company from $167.00 to $165.00 in a research note on Friday, September 23rd. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $175.65.

In other news, insider Linda M. Tharby sold 11,704 shares of the business’s stock in a transaction on Tuesday, September 6th. The stock was sold at an average price of $177.27, for a total value of $2,074,768.08. Following the sale, the insider now owns 22,146 shares of the company’s stock, valued at approximately $3,925,821.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Stephen Sichak sold 10,352 shares of the business’s stock in a transaction on Friday, November 4th. The stock was sold at an average price of $176.10, for a total value of $1,822,987.20. Following the completion of the sale, the insider now directly owns 26,892 shares in the company, valued at approximately $4,735,681.20. The disclosure for this sale can be found here. 1.60% of the stock is owned by insiders.

About Becton Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

Related posts

Leave a Comment